A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

NCT ID: NCT03844256

Last Updated: 2022-08-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-07
• Study Completion Date: 2026-07-31

Brief Summary

A multicenter Phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy in adult (>18 years) subjects with non-metastatic muscle invasive bladder cancer that qualify for ChRT with curative intent.

Detailed Description

Immunotherapy combined with chemoradiation for localized bladder cancer may exhibit improved efficacy with an acceptable toxicity profile.

The aim of this phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy stuy is: to assess the feasibility and safety, the disease free survival (DFS) and disease free survival rate (DFS-rate) of the addition of nivolumab and/or ipilimumab to MMC/capecitabine chemoradiation of the bladder.

Conditions

Urinary Bladder Cancer; Invasive Bladder Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Regimen A

Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.

All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Group Type: EXPERIMENTAL

nivolumab 480mg

Intervention Type: COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Regimen B

Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.

All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Group Type: EXPERIMENTAL

nivolumab 3mg/kg, ipilimumab 1mg/kg

Intervention Type: COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Regimen C

Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.

All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.

Group Type: EXPERIMENTAL

nivolumab 1mg/kg, ipilimumab 3mg/kg

Intervention Type: COMBINATION_PRODUCT

Immuno-chemoradiotherapy

Interventions

nivolumab 480mg

Immuno-chemoradiotherapy

Intervention Type: COMBINATION_PRODUCT

nivolumab 3mg/kg, ipilimumab 1mg/kg

Immuno-chemoradiotherapy

Intervention Type: COMBINATION_PRODUCT

nivolumab 1mg/kg, ipilimumab 3mg/kg

Immuno-chemoradiotherapy

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

mitomycin-c 12mg/m2 IV; capecitabine 750mg/m2; radiotherapy 40Gy in 20 fractions of 2Gy; mitomycin-c 12mg/m2 IV; capecitabine 750mg/m2; radiotherapy 40Gy in 20 fractions of 2Gy; mitomycin-c 12mg/m2 IV; capecitabine 750mg/m2; radiotherapy 40Gy in 20 fractions of 2Gy

Eligibility Criteria

Inclusion Criteria

• Be willing and able to provide written informed consent for the trial.
• Be ≥ 18 years of age on day of signing informed consent.
• Wish to preserve their bladder function or be ineligible for cystectomy.
• Must have undergone transurethral biopsy of the bladder tumor, within 35 days of planned treatment commencement. The patient should have a histologically-confirmed diagnosis of muscle-invasive T2-T4a, N0-1M0 urothelial cell carcinoma of the bladder.
• Must have undergone maximal transurethral resection of the bladder tumour, to an extent that is judged as safe by the urologist performing the resection, within 35 days of planned treatment commencement.
• Subjects with tumors of mixed urothelial/non-urothelial cell histology are allowed, but urothelial cell carcinoma must be the predominant histology (>50%). Subjects with predominant or exclusively non-urothelial cell histology are not allowed.
• Have planned for chemoradiotherapy as definitive treatment.
• Have a performance status of 0 or 1 on the ECOG Performance Scale
• Have a bladder function that is accessible for cystoscopical follow up.
• Demonstrate adequate organ function. All screening labs should be performed within 28 days of registering the patient on the trial.
• Female participants of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registering the patient. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Female participants of childbearing potential should be willing to one highly effective method of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 month after the last dose of study medication Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
• Male participants should agree to use condoms starting with the first dose of study therapy through 7 month after the last dose of study therapy.
• Willing to consent to the use of their collected tumor specimen, blood and urine as detailed in the protocol for future scientific research including but not limited to DNA, RNA and protein based biomarker detection.

Exclusion Criteria

• Has DPD deficiency.
• Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) urothelial cell carcinoma of the urothelium. Patients who have involvement of the prostatic urethra with urothelial cell cancer may be included if the location can be safely incorporated in the radiation field.
• Extensive or multifocal bladder carcinoma in situ (CIS) precluding curative chemoradiotherapy.
• Evidence of distant metastatic disease on a CT or FDG PET/CT chest/abdomen/pelvis performed within 28 days prior to study entry. Up to 3 metastatic lymphnodes in the pelvis (below the common iliac arteries) are allowed, if these can be incorporated in the radiotherapy field.
• Prior pelvic lymph-adenectomy
• Prior pelvic radiotherapy
• Has had prior intravenous chemotherapy, targeted small molecule therapy, or radiation therapy for treatment of bladder cancer. Prior intravesical use of BCG and MMC is permissible.
• Unsuitable for concurrent MMC / capecitabine based ChRT based on pre-existing medical conditions.
• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of treatment.
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy over 10mg daily prednisone (or equivalent) or any other form of immunosuppressive therapy within 14 days prior to registering the patient. Patients with adrenal insufficiency receiving replacement dose steroids are allowed on the trial.
• Has a known history of active TB (Bacillus Tuberculosis)
• Hypersensitivity to nivolumab and/or ipilimumab or any of its excipients.
• Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA <5)
• Has any history of active autoimmune disease, Stevens-Johnson syndrome or Guillain-Barre. Exceptions to this are:

1. Patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone

2. Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen

• Has known history of, or any evidence of active, non-infectious pneumonitis.
• Has an active infection requiring systemic therapy.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
• Has an Human Immunodeficiency Virus (HIV) infection with a PCR detectable viral load.
• Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
• Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

Sponsor Role: lead

Responsible Party

Adriaan D. Bins

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Adriaan D. Bins, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, AMC

Locations

Amsterdam UMC, VUmc

Amsterdam, North Holland, Netherlands

Site Status: RECRUITING

Amsterdam UMC, AMC

Amsterdam, North Holland, Netherlands

Site Status: RECRUITING

LUMC

Leiden, South Holland, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Adriaan D. Bins, MD PhD

Role: CONTACT

a.d.bins@amc.uva.nl

0205662339

Facility Contacts

Adriaan D. Bins, MD PhD

Role: primary

Adriaan D. Bins, MD PhD

Role: primary

Tom van der Hulle, MD, PhD

Role: primary

T.van_der_Hulle@lumc.nl

+31 (0) 71-5298849

Other Identifiers

CA2099TT

Identifier Type: -

Identifier Source: org_study_id